Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00240292
Status:
COMPLETED
Last Update Posted:
2010-11-19
First Post:
2005-10-16
Brief Title:
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Double-blind Randomised Placebo-controlled Parallel-group Multicentre Phase III Study to Assess the Impact of Rosuvastatin Treatment for 26 Weeks Titrated to a Maximum Dose of 40mg Once Daily on Left Ventricular Function Cytokines and Lipid Parameters in Patients With Established Systolic Chronic Heart Failure
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the effect of rosuvastatin up-titrated to a dose of 40mgday compared to placebo on cardiac remodelling estimated by change in left ventricular ejection fraction on radionuclide ventriculography at 26 weeks post randomisation from baseline
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None